Αρχική World News EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin World News EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin Από Ogkologos - 30 Απριλίου, 2025 615 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma 6 Σεπτεμβρίου, 2022 Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations 10 Οκτωβρίου, 2018 Sustainability a major focus of our 17th year partnering with TK... 11 Οκτωβρίου, 2021 FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma 11 Ιουνίου, 2024 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Eribulin Intratumoural Administration of the Oncolytic Herpes Virus Shows Survival Benefit and... Cómo aprendí a sobrellevar la culpa del superviviente después del cáncer Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press...